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Abstract
Vertebrate heart development is strictly regulated by temporal and spatial
expression of growth and transcription factors (TFs). We analyzed nine TFs,
selected by in silico analysis of an Nkx2.5 enhancer, for their ability to transactivate
the respective enhancer element that drives, specifically, expression of genes in
cardiac progenitor cells (CPCs). Mzf1 showed significant activity in reporter assays
and bound directly to the Nkx2.5 cardiac enhancer (Nkx2.5 CE) during murine ES
cell differentiation. While Mzf1 is established as a hematopoietic TF, its ability to
regulate cardiogenesis is completely unknown. Mzf1 expression was significantly
enriched in CPCs from in vitro differentiated ES cells and in mouse embryonic
hearts. To examine the effect of Mzf1 overexpression on CPC formation, we
generated a double transgenic, inducible, tetOMzf1-Nkx2.5 CE eGFP ES line.
During in vitro differentiation an early and continuous Mzf1 overexpression inhibited
CPC formation and cardiac gene expression. A late Mzf1 overexpression,
coincident with a second physiological peak of Mzf1 expression, resulted in
enhanced cardiogenesis. These findings implicate a novel, temporal-specific role of
Mzf1 in embryonic heart development. Thereby we add another piece of puzzle in
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PLOS ONE | DOI:10.1371/journal.pone.0113775 December 1, 2014 1/2 4understanding the complex mechanisms of vertebrate cardiac development and
progenitor cell differentiation. Consequently, this knowledge will be of critical
importance to guide efficient cardiac regenerative strategies and to gain further
insights into the molecular basis of congenital heart malformations.
Introduction
The understanding of underlying principles in cardiogenesis is crucial to identify
pathophysiological mechanisms involved in congenital heart disease and to gain
further insights into the molecular basis for a cardiac regenerative therapy [1–3].
Vertebrate heart development is strictly regulated by temporal- and spatial-
restricted expression of different growth and transcription factors (TFs) [1,2].
Several cardiac progenitor cell populations, which have been characterized by the
expression of different TFs or defined by the activity of specific enhancer elements
using transgenic models, are involved in the developmental processes that guide
cardiogenesis [3–6]. In our study we focused on a murine cardiac progenitor cell
(CPC) population defined by the activity of an Nkx2.5 cardiac enhancer (Nkx2.5
CE) element located about 9 kb upstream of the Nkx2.5 start codon [3,7]. This
CPC population has been described to represent the first identifiable heart-
forming cell population in the developing mouse embryo [3].
The myeloid zinc finger protein 1 (Mzf1) is a Kru ¨ppel class zinc finger TF
preferentially expressed in hematopoietic stem cells, myeloid progenitor cells, as
well as in differentiated myeloid cells [8-10]. Mzf1 is associated with
hematopoiesis as transcriptional regulator in committing hematopoietic precursor
cells to a myeloid fate, especially for granulopoiesis [8,11,12]. Additionally, several
reports also suggest a role of Mzf1 in tumorigenesis influencing cell migration and
invasion [13–16]. Mzf1 has thirteen zinc finger motifs arranged in two different
DNA binding domains which recognize the consensus sequences 59 AGTGGGGA
39 (zinc fingers 1–4) and 59 CGGGNGAGGGGGAA 39 (zinc fingers 5–13) [8,11].
Mzf1 can act as transcriptional activator or inhibitor in a context dependent
manner as shown for a subset of different cell lines [8].
In this study we analyzed nine candidate TFs, selected by in silico analysis of the
Nkx2.5 CE, with a known background in embryonic cardiogenesis or
hemangiogenesis, for their ability to transactivate the Nkx2.5 CE element [3,7].
We found, that Mzf1 displayed an impressive activation of Nkx2.5 CE in luciferase
reporter assays and we were able to demonstrate specific binding of Mzf1 to the
Nkx2.5 CE. In support of a potential role of Mzf1 in cardiac development, we
could show that Mzf1 is highly expressed in embryonic CPCs in vivo. To dissect
the role of Mzf1 in cardiac differentiation, we generated a doxycyclin inducible
Mzf1 overexpressing murine Nkx2.5 CE eGFP ES cell line and examined the
differential effects of Mzf1 on CPC formation. Interestingly, Mzf1 was able to
either repress or enhance cardiogenesis in a temporal-specific manner as indicated
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+ cells and the degree of cardiac gene expression. Thus,
our findings support a novel bi-phasic role of Mzf1 during embryonic heart
development.
Materials and Methods
Methods are described briefly. Please find a detailed methods section in the online
supporting information (Methods S1).
Luciferase Reporter Assays
Cells (HEK 293, H9c2, HL-1 and NFPE) were seeded in 24-well plates and grown
to 70–80% confluence. HEK 293 and H9c2 cells are commercially available at
ATCC (Manassas, VA). HL-1 cells were a kind gift of Prof. Dr. William Claycomb
[17]. NFPE cells were a kind gift of Prof Dr. Karl-Ludwig Laugwitz but are also
commercially available at ATCC. Each well of cells was co-transfected with four
plasmids: the expression plasmid (pcDNA3.1(2) containing the candidate cDNA;
150 ng), a pCMV b-Gal plasmid (to normalize transfection efficiency, 50 ng), the
pBluescript KSII(+) (250 ng, to normalize the quantity of DNA used in each
transfection) and a promoterless pGL3 basic reporter plasmid containing the 2.5
kb fragment of the Nkx2.5 CE including the base promoter [3] in front of a
luciferase gene (150 ng). In further experiments additional mutant forms of the
pGL3-Nkx2.5 CE BP plasmid were used (mutation of the Mzf1 and Mesp1
binding sites). The empty pcDNA3.1 was used as a negative control in all assays.
After 48 h cells were lysed, luciferase activity was determined and normalized to
b-galactosidase activity. Each transfection experiment was performed in triplicate
in at least three independent experiments.
Electromobility Shift Assays (EMSA)
Proteins (Mzf1, Mesp1) were translated in vitro by a TNT T7-coupled reticulocyte
lysate system (Promega, Madison, WI). Pairs of complementary Cy5- or Cy3-
tagged oligonucleotides were annealed overnight and binding reactions were
performed with 5-10 mlo fin vitro translated protein (Mzf1, Mesp1; confirmed by
Western Blot with specific antibodies) or the same amount of unprogrammed
reticulocyte lysate (RL) as a negative control. For competition assays unlabeled
specific competitor (same sequence as the Cy5-tagged probes, 10- and 50-fold
excess) and mutant competitor (10-fold excess) were added to test for specifity of
DNA binding. Three independent experiments were performed.
Chromatin Immunoprecipitation (ChIP) Assays
Cross-linking of day 9 differentiated Nkx2.5 CE eGFP ES cells (a kind gift of Dr.
Sean M Wu [3]) was achieved by incubating the cells with 1% formaldehyde for
30 min at RT. For subsequent sonication cell-lysates were diluted and DNA was
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or an isotype-matched control and pulled down by protein A/G-Sepharose beads.
Immune complexes were washed extensively with buffer (increasing stringency)
and eluted by boiling in SDS sample buffer. DNA purification was performed and
with the primer sets #1 (forward 59 TAC CGG CAG AGA CTG AAG TTT 39,
reverse 59 ATT AGT GTG AAC ACA ACA CTC G 39 corresponding to -9340 to -
9220 of the Nkx2.5 CE, fragment size 121 nt), #2 (forward 59 AAG CTT GGC
GTG TGA CAT TGT 39, reverse 59 GAT TGT GAA CCG GTA GGC GG 39
corresponding to -9123 to -8921 of the Nkx2.5 CE, fragment size 203 nt), #3
(forward 59 TGA GCG CCG CCG TTT ATG CT 39, reverse 59 GAT GGA TCC
GAT GGG AGC TG 39 corresponding to -8360 to -8246 of the Nkx2.5 CE,
fragment size 114 nt) and #4 (forward 59 AAA TCA ATC ACA GCC CCA AGT G
39, reverse 59 GTT TAT GGA AAA CTC AAA TAG CAG 39, corresponding to
28235 to 28048 of the Nkx2.5 CE, fragment size 188 nt) the appearance of
specific parts of the Nkx2.5 CE was validated. The precipitation of background
DNA was controlled by an amplification with primers against b-Actin (fragment
size 97 nt, primer sequence see Table S2). PCRs were performed with equal
volumes of Mzf1 chip’d samples and the corresponding IgG control on a Thermo
Cycler (Bio-Rad, Munich, Germany) and 35 cycles.
Site Directed Mutagenesis
All mutant forms of the pGL3-Nkx2.5 CE BP plasmid were constructed by long
polymerase chain reaction-based techniques using the QuikChange Multi Site-
Directed Mutagenesis Kit with PfuTurbo polymerase (Stratagene, La Jolla, CA)
and different primers containing the desired mutations (for two putative Mzf1
and two Mesp1 binding sites). After amplification all methylated and
hemimethylated DNA was digested with the restriction enzyme DpnI followed by
a transformation of the remaining mutated single stranded DNA into XL10 Gold
ultracompetent cells. The correct DNA sequence of all constructs was confirmed
by DNA sequencing.
Animals
Mice were housed in an accredited facility in compliance with the European
Community Directive related to laboratory animal protection (2010/63/EU). All
transgenic mouse lines have been described in detail previously. For extraction of
embryos or organs mice were first anesthetized with isoflurane (2-chloro-2-
(difluoromethoxy)-1,1,1-trifluoro-ethane) and then euthanized by cervical
dislocation. Embryos of the Nkx2.5 CE eGFP transgenic mice [3] were collected
on E 9.5 from timed matings (a positive mating plug indicates E 0.5). Mouse
embryos were used for FACS analysis as described in the respective sections.
aMHC-Cre/ROSA26
mT/mG transgenic mice [18] were provided for heart
extraction for FACS analysis as described in the respective section. All animal
experiments, like organ or embryo extractions, were performed in accordance
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were approved by the Regierung von Oberbayern.
Lentiviral transduction of ES cells
We used a previously described doxycyclin inducible lentiviral tet-on expression
system [19] (a kind gift of Dr. K. Hochedlinger) modified with an IRES
puromycin element. The murine complete Mzf1 cDNA tagged by a flag sequence
was subcloned into the modified pLvtetO backbone in front of the IRES element.
Lentivirus production by 293 cells was previously described by Gregoire et al. [20].
For transduction the virus containing supernatant was collected after 48 h, filtered
and then directly used without further concentration.
A doxycyclin inducible tetOMzf1-Nkx2.5 CE eGFP ES cell line was established
by co-transducing Nkx2.5 CE eGFP ES cells with tetOMzf1-IRES-puromycin and
rtTA lentiviral particles (approved by the Regierung von Oberbayern, Az. 50-
8791-26.384.1776). Antibiotic selection was performed with doxycyclin (dox) and
puromycin. About 10 days post-transduction, colonies were individually
expanded and scored by qRT-PCR for sufficient expression of Mzf1. Morphology
and growing behavior of the transduced cell lines were virtually indistinguishable
from untreated murine ES cells.
Flow cytometry
Single cell suspension was prepared from Nkx2.5 CE eGFP and dox-inducible
tetOMzf1-Nkx2.5 CE eGFP differentiating ES cells. Nkx2.5 CE eGFP mouse
embryos were dissected on E 9.5 and single cell suspension was obtained. Adult
cardiomyocytes (CMs) were isolated from six week old aMHC-Cre/ROSA26
mT/mG
mice. Dead cells were stained with propidium iodide solution for flow cytometry.
RNA Isolation and qRT-PCR
Total RNA was isolated and reverse transcribed into first strand cDNA.
Semiquantitative real time PCR (qRT-PCR) was performed using gene-specific
primer sets (Table S2) for 40 cycles. DCT calculations were performed and each
sample was normalized against its b-actin value.
Data Analysis and Statistical Analysis
All assays were at least performed in triplicates. Data are presented as mean values
¡ standard error (S.E.M.). Statistical differences were evaluated using the
unpaired Student’s t-test or the Mann-Whitney-U test. Comparison of several
groups was done by one way ANOVA or the Kruskal-Wallis test on ranks
including appropriate post-hoc tests. A value of p ,0.05 was considered to be
statistically significant. In all figures statistical significance is indicated as follows: *
p ,0.05 and ** p ,0.01.
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An in silico transcription factor (TF) binding site analysis [21] (P-Match [22]
http://www.gene-regulation.com/cgi-bin/pub/programs/pmatch/bin/p-match.cgi,
PROMO 3.0 http://alggen.lsi.upc.es/recerca/menu_recerca.html, JASPAR database
http://jaspar.genereg.net, ConSite http://phylofoot.org/consite, TFSEARCH ver.
1.3 http://www.cbrc.jp/research/db/TFSEARCH.html) of the cardiac specific
Nkx2.5 enhancer [7]( 29641 to 27540 bp upstream of the murine Nkx2.5
transcriptional initiation site) and the base promoter [3]( 2520 to 224 bp
upstream of the ATG of the Nkx2.5 gene) revealed a couple of candidates for
potential interaction (Table S1). Nine of these TFs (Gata4 [7], Hand1 [23], Sox17
[24], Klf4 [25], Elk1 [26], Msx1 [27], Mzf1, Brachyury [28], Mesp1 [29]) which are
known in the context of embryonic heart development or hemangiogenesis were
selected for further analysis.
Mzf1 strongly activates the Nkx2.5 CE using different cell lines
Luciferase reporter assays were performed to evaluate the activation capacity of
the candidate TFs on the Nkx2.5 CE. Each TF was inserted into a modified
pcDNA3.1 vector and co-transfected with the Nkx2.5 CE luciferase reporter
plasmid (Fig. 1A) in HEK 293 cells. A more than 5-fold activation of the luciferase
gene was found for Elk1, Klf4, Mesp1 and Mzf1 (Fig. 1B).
To determine if this effect is cell line specific, luciferase assays were also
performed in H9c2, a rat myoblastic cell line corroborating a strong (more than
30-fold) transgene activation by Mesp1 and Mzf1 (Fig. 1C). Further luciferase
assays using murine atrial HL-1 cells confirmed the induction of luciferase
expression by Mzf1 (Fig. 1D) and Mesp1 (Fig. S1A). Interestingly no transacti-
vation of either factor occurred in endothelial NFPE cells (Fig. 1D, Fig. S1A).
Luciferase induction occurred in a dose-dependent fashion for both TFs in HEK
293 cells (Fig. 1E, Fig. S1B).
Our results confirmed the findings reported by Bondue et al. [29] regarding the
interaction between Mesp1 and the cardiac specific Nkx2.5 CE element. However,
we were intrigued by the as yet unknown function of Mzf1 during
cardiomyogenesis. Hence, we chose to further explore the role of Mzf1 in this
context.
Mzf1 shows activating effects on different parts of the Nkx2.5 CE
According to Lien et al. [7] the identified Nkx2.5 CE consists of activating and
non-activating elements regarding the potential to drive a cardiac specific b-
galactosidase expression. Corresponding to their description we investigated the
potential of Mzf1 and Mesp1 to induce luciferase expression driven by different
parts of the Nkx2.5 CE (29641 to 29119; 29119 to 8240; 28240 to 27540).
Luciferase activity was significantly reduced following Mzf1 and Mesp1 treatment
when the Nkx2.5 CE was truncated, regardless which part of the Nkx2.5 CE was
used for the assay, suggesting the presence of activating binding sites in each
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that one of the truncated fragments contains a binding site of Mzf1, while the
others contain binding sites for essential co-factors.
Figure 1. TF screening on the Nkx2.5 CE element by luciferase reporter assays. A. Plasmid constructs for luciferase reporter assays. The empty
modified pcDNA3.1 was used as a negative control in all assays. B. TF screening by luciferase assays using HEK 293 cells (human embryonic kidney
fibroblasts). Fold change is compared to the negative control (neg ctr) (pcDNA3.1). C. TF screening by luciferase assays using H9c2 cells (rat myoblasts).
Fold change is compared to the negative control (neg ctr) (pcDNA3.1). D. Mzf1 activates the Nkx2.5 CE element in atrial HL-1 cells but not in endothelial
NFPE cells. Asterisks indicate a significant difference compared to the control (pcDNA3.1); ** 5 p ,0.01. E. Dose dependent effect of Mzf1-pcDNA3.1-DNA
on Nkx2.5 CE activation in HEK 293 cells; * 5 p ,0.05. F. Effect of truncating different parts of the Nkx2.5 CE according to Lien and co-workers [7]o n
luciferase activation by Mzf1 in HEK 293 cells.
doi:10.1371/journal.pone.0113775.g001
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Since in silico analysis of the Nkx2.5 CE revealed between 19 and 92 potential
binding sites for Mzf1 (Table S1) distributed all over the Nkx2.5 CE, we decided to
focus on two binding motifs similar to the well-known zinc finger motifs already
described by other researchers [8,11].
The binding of Mzf1 to the Nkx2.5 CE could be confirmed by electromobility
shift assays (EMSA) using the core Mzf1 binding motif 59-AGGGGGA-39
(corresponding to the zinc fingers 5–13, [8,11]) at position 29430 bp of the
Nkx2.5 CE using Cy5-tagged probes and in vitro translated Mzf1 protein (Fig. 2A–
C). Competition assays with untagged mutant (10-fold excess) and specific probes
(10- and 50-fold excess) were performed to ensure specificity of the binding
reaction at position 29430 (Fig. 2D). However, binding to the motif 59-
GTGGGGA-39 (corresponding to the zinc fingers 1–4, [8,11]) at position 28181
bp of the Nkx2.5 CE could not be approved by EMSA (Fig. 2E). Direct binding of
in vitro translated Mesp1 to the Nkx2.5 CE was also confirmed by EMSA (Fig.
S1D–F).
To further corroborate Mzf1 binding to the Nkx2.5 CE in vivo ChIP assays with
a polyclonal anti-Mzf1 antibody were performed on cross-linked murine day nine
differentiated Nkx2.5 CE eGFP ES cells followed by PCR analysis (Fig. 2F).
Chromatin shearing led to fragment sizes between 250 and 1000 bp (Fig. 2G).
Binding of Mzf1 on day nine of in vitro differentiation of murine ES cells could be
validated with primer set #3 corresponding to a 114 nt fragment at position
28360 to 28246 of the Nkx2.5 CE (Fig. 2A+H) and primer set #4 corresponding
to a 188 nt fragment at position 28235 to 28048 of the Nkx2.5 CE (Fig. 2A+H).
Primer set #1( 29340 to 29220) led to a darker band in the sample precipitated
with the anti-Mzf1 antibody compared to the control but the background was
very strong for this primer set (Fig. 2H). No binding could be confirmed with
primer set #2( 29123 to 28921) (Fig. 2H). A background control with primers
against b-Actin approved that precipitation of unspecific DNA was low (Fig. 2H).
In a next step site directed mutagenesis was performed on the pGL3-Nkx2.5 CE
BP plasmid to mutate the analyzed binding sites of Mzf1 (Fig. 2I) and also Mesp1
(Fig. S1G). Subsequent luciferase assays with the Mzf1-pcDNA3.1 could not show
a reduced luciferase activity when only one, either at position 29430 bp or 28181
bp, of the binding sites in the Nkx2.5 CE was mutated (Fig. 2I). However, a
combined mutation of both binding sites led to a significant reduction of about
30% of luciferase activity (Fig. 2I). For Mesp1 we could confirm the significance of
the binding site at position 229 bp by a significant reduction of luciferase activity
by 26% (Fig. S1G) when this site was mutated as already indicated by ChiP-assays
by Bondue and co-workers [29]. No reduction of luciferase activity could be
shown for a mutation of the Mesp1 binding site at position 29138 bp, despite
ChiP-assays demonstrated binding of Mesp1 to this site [29].
Role of Mzf1 in Cardiogenesis
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murine ES cell lines
Next we analyzed the kinetics of Mzf1 mRNA expression during ES cell in vitro
differentiation. Three different murine ES cell lines (V6.5 ES, the transgenic
Nkx2.5 CE eGFP ES [3] and the transgenic aMHC-Cre/ROSA26
mT/mG ES [18])
were studied every other day starting from day 0 of differentiation (when hanging
drops are prepared) for the expression of Mzf1 (for experimental set-up see
Fig. 3A). We found a clear biphasic mRNA expression pattern of Mzf1 in all of the
three ES cell lines with an early peak around day two and a second peak between
day eight and day ten of in vitro differentiation (Fig. 3B).
Mzf1 gene expression is upregulated in CPCs but not in adult
cardiomyocytes
As previously described, luciferase reporter assays indicated an activation of the
Nkx2.5 CE element by Mzf1. Additionally, specific binding of Mzf1 to the Nkx2.5
CE element could be confirmed by EMSA and ChIP assays.
We postulated that if Mzf1 interacts with the Nkx2.5 CE in vivo it should also be
differentially expressed within Nkx2.5 CE eGFP positive CPCs (Fig. 4A). To
examine this hypothesis, we differentiated Nkx2.5 CE eGFP ES cells for either five
or seven days. During in vitro differentiation of this cell line first eGFP positive
CPCs usually emerge on day five. EGFP-positive CPCs and eGFP-negative cells
were then isolated by fluorescence activated cell sorting (FACS) on day five and
seven. Both cell populations were lysed for total RNA extraction and subsequent
gene expression analysis by qRT-PCR (Fig. 4E). We observed that CPCs expressed
a considerably higher level of Mzf1 than non-CPCs, on day five and seven of in
vitro differentiation (Fig. 4F). These isolated eGFP positive CPCs further exhibit
high expression levels of typical early cardiac marker genes compared to eGFP
negative non-CPCs (Fig. 4H).
Figure 2. Direct binding of Mzf1 to the Nkx2.5 cardiac enhancer in vitro and in vivo.A .Locations of
analyzed described Mzf1 binding motifs in the Nkx2.5 CE [8,11] (black triangles) and primer sets #1-#4 for
ChIP PCR (grey rectangles with numbers). B. In vitro translated Mzf1 protein from the flag-Mzf1-pcDNA3.1
confirmed by an anti-flag antibody in western-blotting (lane 3). As a control whole cell lysates from 293 cells
transfected with the flag-Mzf1-pCDNA3.1 plasmid were used (lane 1 & 2). The predicted molecular weight for
Mzf1 is 84 kDa. C. Different amounts of in vitro translated Mzf1 (10ml, 5ml) bound to the Nkx2.5 CE at the
binding motif corresponding to zinc fingers 5-13 (black triangle at position -9430 bp) [8,11] in an electromobility
shift assay (EMSA). Unprogrammed reticulocyte lysate (RL) was applied as a control. D. Competition assays
with untagged mutant (mut, 10-fold excess) and specific probes (10- and 50-fold excess) were performed to
ensure specificity. E. In vitro binding to the motif corresponding to zinc fingers 1-4 (at position 28181 bp) [8,11]
by EMSA could not be confirmed. Different amounts of in vitro translated Mzf1 (10ml, 5ml) were used.
Unprogrammed reticulocyte lysate (RL) was applied as a control. F. Experimental set-up for ChIP assays.
Chromatin was isolated from day nine differentiated Nkx2.5 CE eGFP ES cells. G. Chromatin was sheared by
sonication to obtain fragment sizes between 250 and 1000 bp. H. ChIP-PCR on purified chromatin using a
polyclonal anti-Mzf1 and an isotype-matched control antibody. Lane 1: 4% sonicated input chromatin. Lane 2:
Chromatin precipitated with the Mzf1 antibody. Lane 3: Chromatin precipitated with an IgG matched control
antibody. I. Effect of mutating two Mzf1-binding sites at positions 29430 bp and -8181 bp in the Nkx2.5 CE on
luciferase activity by Mzf1 in HEK 293 cells (** 5 p ,0.01).
doi:10.1371/journal.pone.0113775.g002
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pregnant transgenic Nkx2.5 CE eGFP mice were dissected on day E 9.5 where
eGFP expression and thus Nkx2.5 CE activity peaks during embryonic
development [3]. Whole embryos were digested by a collagenase mixture to
obtain single cell suspension for accomplishing FACS. As analyzed by qRT-PCR
Mzf1 expression in eGFP positive cells, which exclusively correspond to the E 9.5
heart (Fig. 4C) was more than 80-fold upregulated when compared to the level in
embryonic eGFP negative cells (Fig. 4G).
To determine the relative expression of Mzf1 in more mature cardiomyocytes,
we utilized the aMHC-Cre/ROSA26
mT/mG [18] transgenic murine ES cell line for
further experiments. Mature cardiomyocytes (CMs) expressing aMHC switch
from red to green fluorescence which is induced by Cre-mediated excision of the
td-tomato expression cassette (Fig. 4B). GFP positive CMs were isolated by FACS
on day 15 of differentiation. In contrast to CPCs the more mature eGFP positive
CMs do not show an elevated level of Mzf1 compared to the eGFP negative
population (Fig. 4F). A more detailed gene expression profile of isolated CMs
including typical cardiac and sarcomeric markers is presented in Fig. 4I.
Furthermore, also isolated eGFP positive CMs from postnatal hearts of the
aMHC-Cre/ROSA26
mT/mG transgenic mice (. three weeks of age), do not show a
similar elevation over non-cardiomyocytes when compared to E 9.5 CPCs
(Fig. 4G).
Figure 3. Biphasic kinetics of Mzf1 expression during in vitro differentiation. A. Experimental set-up for in vitro differentiation assays of three different
murine ES cell lines for the evaluation of time-dependent Mzf1 expression levels. B. Mzf1 expression levels showed a biphasic course during in vitro
differentiation of aMHC-Cre/ROSA26
mT/mG -, Nkx2.5 CE eGFP - and V6.5 ES cells; * 5 p ,0.05; ** 5 p ,0.01.
doi:10.1371/journal.pone.0113775.g003
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PLOS ONE | DOI:10.1371/journal.pone.0113775 December 1, 2014 11 / 24Figure 4. Differential expression of Mzf1 in cardiac progenitor cells (CPCs) but not in cardiomyocytes (CMs) and gene expression profiles of in
vitro differentiated CPCs and CMs. Scale bars: 200 mm for all panels, except C: 500 mm. A.-D. Detection of CPCs and mature CMs by activation of eGFP
expression. Illustration of transgenic cell lines (A.–B.) and animal models (C.–D.). E. Experimental set-up for isolating eGFP-positive and -negative cell
populations by FACS. F. Gene expression analysis after FACS sorting of in vitro differentiated Nkx2.5 CE eGFP ES cells (A.) revealed a considerable up-
regulation of Mzf1 in eGFP
+ CPCs but not for mature CMs (B.) compared to the respective eGFP
2 cells. G. Correspondingly, Mzf1 expression was up-
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differentiation
Next, to directly address the effect of Mzf1 on CPCs and on cardiac differentiation
in general, we generated a double-transgenic, doxycyclin (dox) inducible Mzf1
over-expressing murine ES cell line by lentiviral transduction of the transgenic
Nkx2.5 CE eGFP ES cell line (tetOMzf1-Nkx2.5 CE eGFP ES). A plasmid driving
dox-inducible expression of Mzf1 and puromycin resistance separated by an
internal ribosome entry site (IRES) was co-transduced with a plasmid that
constitutively expresses a reverse tetracycline transactivator (rtTA) (Fig. 5A, Fig.
S2A). Sufficient inducibility of Mzf1 expression was confirmed in three cell lines
(clones 42, 44 and 64; Fig. S2B). Furthermore, it was proofed that Mzf1
overexpression decreased steadily after stopping dox supplementation of the
medium (Fig. S2C–D). Two days after dox-removal the Mzf1-mRNA-level was
more than 50% reduced compared to the starting level. And after four days the
Mzf1-mRNA-level was not different from the samples without dox-addition.
Morphology (Fig. S2E), pluripotency (Fig. S2F, anti Sox2 immunostaining) and
Mzf1-expression (p 5 0.242) were comparable between the tetOMzf1-Nkx2.5 CE
eGFP ES cell line without dox treatment, and the parent Nkx2.5 CE eGFP ES cell
line.
In vitro differentiation assays of the tetOMzf1-Nkx2.5 CE eGFP ES cell line were
performed by the standard hanging drop method [30] to assess the effects of Mzf1
overexpression on CPC number by flow cytometry. ES cells were differentiated for
eight days. In line with the physiological, biphasic course of Mzf1-mRNA
expression during ES differentiation (Fig. 3B) doxycyclin was added according to
different treatment schedules (Fig. 5B). Besides a permanent Mzf1-overexpression
by dox-treatment (day 0 - 8), time intervals from zero to five and from five to
eight days were analyzed. The tetOMzf1-Nkx2.5 CE eGFP ES cell line
differentiated without dox treatment (ctr w/o dox) was used as reference.
The appearance of eGFP positive, beating cells at day five to six of in vitro
differentiation was indistinguishable between the control (w/o dox) and the
parent murine Nkx2.5 CE eGFP ES cells (Fig. S2G, Video S1, S2).
The comparable amount of dead cells between the different approaches (Fig.
S2H) identifiable by propidium iodide staining using FACS analysis indicated that
the overexpression of Mzf1 did not influence cell viability during in vitro
differentiation.
Cell proliferation was additionally controlled by MTT assays. Whereas
tetOMzf1-Nkx2.5 CE eGFP ES cells which grew with dox for 48h were
indistinguishable from their untreated counterparts (p 5 0.927), ES cells treated
regulated in eGFP
+ CPCs isolated from E 9.5 embryos (C.) but not to a comparable amount in mature CMs isolated from postnatal (. 3 weeks) hearts (D.)
compared to the respective eGFP
2 cells. H. Nkx2.5 CE eGFP ES cells were differentiated till day 5–7. GFP positive (CPCs) and GFP negative cells were
sorted by FACS. Gene expression profiles of typical cardiac developmental marker genes (Nkx2.5, Mef2c, Gata4, Tbx20, etc.) were evaluated by qRT-PCR.
I. aMHC-Cre/ROSA26
mT/mG ES cells were differentiated till day 15. GFP positive (CMs) and GFP negative cells were sorted by FACS. Gene expression
profiles of typical cardiac and sarcomeric marker genes (Tnnt2, aMHC, etc.) were evaluated by qRT-PCR.
doi:10.1371/journal.pone.0113775.g004
Role of Mzf1 in Cardiogenesis
PLOS ONE | DOI:10.1371/journal.pone.0113775 December 1, 2014 13 / 24with dox for a longer period (five to nine days) proofed significantly more
proliferative (p 5 0.003) (Fig. S2I).
Furthermore, an efficient Mzf1 overexpression during in vitro differentiation
assays was confirmed by qRT-PCR (Fig. S3A) and immunostaining with an anti-
flag antibody detecting only exogenous Mzf1 (Fig. S3B). The Mzf1 expression level
on day 8 was lower in approaches with permanent dox-treatment than in
Figure 5. In vitro differentiation of the double-transgenic dox-inducible Mzf1 overexpressing tetOMzf1-Nkx2.5 CE eGFP ES cell line. Scale bars:
200 mm for all panels. A. Lentiviral constructs for the production of the doxycyclin-inducible tetOMzf1-Nkx2.5 CE eGFP ES line. LTR: long terminal repeats.
TRE: tetracyclin responding element. CMV: cytomegalovirus promoter. IRES: internal ribosomal entry site. rtTA: reverse tetracyclin transactivator. B. In vitro
differentiation protocols with time-schedules of dox-treatment. C. Morphology of differentiating EBs on day eight. Permanent and day 0–5 dox-treatment led
to closely packed globular clusters. In contrast dox-treatment from day 5 showed a normal differentiation pattern comparable to the control w/o dox. D/E.
FACS analysis revealed a significant increase in eGFP
+ CPCs for dox-treatment from day 5 of differentiation whereas a continuous and day 0-5 dox-
treatment resulted in a significant decrease of eGFP
+ CPCs compared to control w/o dox; ** 5 p ,0.01.
doi:10.1371/journal.pone.0113775.g005
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S3A). This may be due to some self-inhibiting mechanisms within Mzf1 regulation
on the mRNA level or due to inactivation of the integrated CMV promoter during
in vitro differentiation or a combination of both.
Mzf1 overexpression from day 5 of in vitro differentiation showed no
morphological differences and also a regular appearance of beating areas
compared to the control w/o dox (Fig. 5C, Video S3). In contrast, permanent
overexpression of Mzf1 (day 0–8) and dox treatment from day 0–5 led to severe
morphological changes. EBs grew in closely packed, globular clusters while no
beating areas could be observed (Fig. 5C).
FACS analysis on day eight of in vitro differentiation revealed about 0.98% ¡
0.070 eGFP positive cells (CPCs) in the negative control (w/o dox). Interestingly,
an overexpression of Mzf1 from day 5 showed 1.27% ¡ 0.090 (p 5 0.003) eGFP
positive cells depicting an increase of nearly 30% compared to the control (w/o
dox) and suggesting an enhancement of cardiogenesis. In contrast, permanent
Mzf1 overexpression significantly reduced the amount of CPCs to 0.085% ¡
0.012 eGFP positive cells (p ,0.001) indicating a strong inhibitory effect on
cardiogenic differentiation. No significant difference of eGFP positive CPCs could
be detected between both protocols with an early overexpression of Mzf1 (day 0–5
and day 0–8) (p 5 0.596) (Fig. 5D+E).
Mzf1 modifies cardiac gene expression
Cardiac gene expression was analyzed by qRT-PCR to confirm results obtained
from flow cytometry in terms of down- or up-regulation of cardiogenesis,
respectively.
Temporary Mzf1 overexpression from day five led to a significantly up-
regulated Nkx2.5 expression compared to the control w/o dox (p 5 0.028). In
contrast, Nkx2.5 was dramatically down-regulated by a permanent Mzf1
overexpression (p ,0.001) (Fig. 6A) confirming regulatory effects of Mzf1 on
CPCs. The regulatory effect was also seen for the cardiac TFs Tbx5, Isl1 and Mef2c
but not for Gata4 (Fig. 6B–E). Furthermore, cardiac structural genes were
significantly repressed by permanent overexpression of Mzf1 whereas a temporary
overexpression led to a significant elevation of cardiac structural genes like a-
MHC and the pancardiac a-Actin (Fig. 6F-G), but not Troponin T (Tnnt2)
(Fig. 6H) (see also western blot, Fig. 6I). The hematopoietic marker Runx1 [31]
was down-regulated by dox-stimulated Mzf1 expression from day five (p ,0.001)
but was not affected by a permanent Mzf1 overexpression (p 5 0.371) (Fig. 6J).
Ectodermal and endodermal differentiation was assessed by the expression of
Nestin and Sox17 [2,24], respectively. Nestin was down-regulated by Mzf1-
overexpression from day 5 (p ,0.001) but was unaffected by a continuous
overexpression (p 5 0.779) (Fig. 6K). Interestingly, Sox17 was unaffected by a late
Mzf1 overexpression (p 5 0.975) but a permanent Mzf1 overexpression led to a
significant increase over the control w/o dox (p ,0.001) (Fig. 6L).
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PLOS ONE | DOI:10.1371/journal.pone.0113775 December 1, 2014 15 / 24Figure 6. Gene expression analysis during in vitro differentiation of tetOMzf1-Nkx2.5 CE eGFP ES cells. * 5 p,0.05; ** 5 p ,0.01 for all panels. A–H.
Expression of selected cardiac genes. PHF: primary heart field. SHF: secondary heart field. I. Protein expression by western-blotting for Tnnt2 and Gapdh. J–L.
Expression of selected hematopoietic (J.), ectodermal (K.) and endodermal (L.) genes. M. Experimental set-up for day three in vitro differentiation assays. N.
MorphologyofdifferentiatingEBsondaythree.Dox-treatmentforthreedaysincreasedcellproliferation.Scalebarsindicate200 mm.O–T.Geneexpressionanalysis
of Mzf1 (O.), Mesp1 (mesodermal) (P.), Flk1 (cardiovascular progenitor marker) (Q.), Tal1, Gata1 (hematopoietic marker) (R., S.) and Nestin (ectodermal) (T.).
doi:10.1371/journal.pone.0113775.g006
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arranged a different experimental set-up for further in vitro differentiation assays
(Fig. 6M). The dox-inducible tetOMzf1-Nkx2.5 CE eGFP ES cell line was
differentiated for only three days with or without addition of dox. Figure 6N
shows that EBs grew faster under permanent dox-treatment for three days which
is in agreement with the increased cell proliferation of tetOMzf1-Nkx2.5 CE eGFP
ES cells that grew with dox for more than 48 h (Fig. S2I). On day three EBs were
harvested and total RNA was applied to qRT-PCR. First, Mzf1 expression was
confirmed by qRT-PCR showing a 58-fold overexpression by dox-treatment
compared to untreated control (p ,0.001, Fig. 6O). Next, we analyzed marker
genes involved in early cardiac development, such as Mesp1, an early cardiac
mesoderm marker [32]o rFlk1 known as an early marker of cardiovascular
commitment [33]. Mesp1 as well as Flk1 were considerably down-regulated by
Mzf1 overexpression (p ,0.001, Fig. 6P-Q), confirming the already assumed
inhibition of cardiogenesis by an early over-expression of Mzf1. Interestingly, Tal1
(also known as Scl), typically expressed in hemangioblasts (progenitor cells of the
hematoendothelial lineage, [34]), as well as Gata1, a marker of the hematopoietic
lineage [35], and Nestin (ectodermal marker), were not affected by an early Mzf1
over-expression for three days (Fig. 6R-T).
Discussion
The specification and differentiation of pluripotent stem cells in vitro and in vivo
is driven by a complex transcriptional regulatory network. Most of the evidence
about the TF Mzf1 and its impact on other genes are exclusively based on in vitro
luciferase assays and EMSA [8,36]. Herein we studied, comprehensively, the role
of Mzf1 on the frequency of cardiac progenitor cells using an Nkx2.5 cardiac
specific enhancer element. We identified for the first time that Mzf1 can activate
the Nkx2.5 CE in several cell lines and that Mzf1 binds directly to the Nkx2.5 CE
both in vitro and in vivo.
Our diverging results of the Nkx2.5 CE activation by Mzf1 in different cell lines
indicates that Mzf1 can act in a cell specific manner as previously implied by
Morris and co-workers [8] for hematopoietic (K562, Jurkat) or nonhematopoietic
cell lines (NIH 3T3, 293). Interestingly, Mzf1 is able to transactivate the Nkx2.5 CE
in muscular and cardiac cell lines such as H9c2 and HL-1 but not in endothelial
cell lines such as NFPE cells. This suggests that the mechanism of Mzf1
transcription is dependent on the presence of tissue-specific regulators or
differential protein modifications that affect Mzf1 function as postulated
previously [8]. Most likely, tissue-specific co-factors are necessary for an
appropriate function within a cellular system, (e.g. YY1 acts together with Gata4
in CPCs [20]). Our finding that Mzf1 interacts with the Nkx2.5 CE raises the
possibility that the binding of Mzf1 to the Nkx2.5 CE may require the presence of
other Nkx2.5 CE-bound TFs [8,11].
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differentiation of murine ES cell lines potentially indicating a dual mode of action
during lineage specification. Other factors like Myf-6 [37] or D-mef2 [38] that
influence lineage specification also act in a biphasic manner during embryonic
development.
Our hypothesis that Mzf1 plays a role in cardiogenesis via an interaction with
the Nkx2.5 CE was further supported by the differential expression of Mzf1 in
purified Nkx2.5 CE positive CPCs at days five and seven of differentiation as well
as in mouse embryonic hearts at E 9.5 but to a much lower extent in mature adult
cardiomyocytes. These results indicate that the main influence of Mzf1 on Nkx2.5
CE labelled CPCs takes place during early cardiomyocyte differentiation but not
after terminal differentiation of these cells.
Since Mzf1 appears to regulate gene expression in CPCs, we examined the effect
of Mzf1 overexpression using a murine tetOMzf1-Nkx2.5 CE eGFP ES cell line.
Flow cytometry results clearly indicated an increased frequency of CPCs induced
by an Mzf1 overexpression from day five of in vitro differentiation. In contrast,
continuous overexpression of Mzf1 from day 0-8 resulted in significant reduction
of CPC formation. We furthermore found evident morphological changes during
differentiation under permanent dox-addition. Settled EBs showed globular
clusters which were closely packed while no beating areas could be observed. It
can be assumed that the permanent Mzf1 overexpression led to a different
migration behavior of cells in these EBs since it is well known that Mzf1 plays a
role in migration and invasion [13–16]. However, Mzf1 overexpression from day 5
exhibited an EB-morphology typical for undirected murine ES-cell differentia-
tions and a regular appearance of beating areas. Based on this observation, we
concluded that Mzf1 overexpression can induce cardiac lineage expansion in a
temporal-specific fashion.
Taken together, our results implicate a role for Mzf1 in the control of cardiac
commitment by an interaction with the Nkx2.5 cardiac enhancer. As Mzf1 was
significantly enhanced in a CPC population in vitro as well as in embryonic heart
tissue and late overexpression of Mzf1 promoted cardiac lineage commitment we
propose that Mzf1 may be a novel regulator of embryonic heart development.
Figure 7 summarizes the physiological biphasic kinetics of Mzf1 expression. The
first peak of Mzf1 up-regulation occurs early during specification of pluripotent
cells: Around day two of in vitro differentiation, corresponding with the epiblast
stage during murine development on E 6.0 or 6.5. At this time Mzf1 seems to have
an inhibitory effect on cardiac lineage commitment as shown by our results
(down-regulation of Mesp1). Mzf1 may inhibit the generation of cardiac
mesoderm by suppressing Mesp1 and Flk1 expression. Runx1 (hematopoietic) and
Nestin (ectodermal) are virtually unaffected by a permanent overexpression of
Mzf1. The second physiological peak of Mzf1 expression occurs during
differentiation of pluripotent cells around day eight of in vitro differentiation. An
overexpression of Mzf1 at the beginning of this peak (from day 5), in parallel with
the endogenous upregulation of the Nkx2.5 expression which is initiated at day
four of in vitro differentiation and is highly increased at day five to seven [3],
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typical cardiac primary heart field (PHF) genes like Tbx5, sarcomeric genes like
aMHC or the pancardiac structural marker cardiac aActin are significantly up-
regulated.
Mzf1 transcriptional regulation mechanisms seem to be tissue-specific as well as
stage dependent. The divergent findings of stimulation or repression of specific
marker genes by time-dependent Mzf1 overexpression supported earlier
suggestions that Mzf1 might be necessary for a normal differentiation program
involving a balance between positive and negative regulatory signals [36].
A global deletion of Mzf1 in the mouse did not lead to embryonic lethality nor
did the authors mention evident alterations during heart development [10]. It
could be speculated that a loss of Mzf1 during development may be compensated
by another transcription factor as it is known for Mesp1 and Mesp2 during the
early stages of gastrulation [39]. However, we have to assume that the role of Mzf1
in heart development is more stabilizing or modulating than actually stimulating.
In summary, the findings that Mzf1 can simultaneously activate or repress
specific genes following time-dependent Mzf1 overexpression support a
Figure 7. Potential mechanistic role of Mzf1 during embryonic development. The first peak of
physiological Mzf1 up-regulation occurs during specification of pluripotent cells, corresponding to the epiblast
stage during murine development on E 6.0 or 6.5. At this time Mzf1 seems to have an inhibitory effect on
cardiac lineage commitment. The second physiological peak of Mzf1 expression occurs during differentiation
of pluripotent cells around day eight of in vitro differentiation. An overexpression of Mzf1 at the beginning of
this peak resulted in stimulation of cardiogenesis.
doi:10.1371/journal.pone.0113775.g007
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between positive and negative regulatory signals is critical. Further investigation of
the role of Mzf1 in cardiac development in vivo may provide novel insights into
molecular mechanisms of vertebrate heart development, which are crucial for
devising successful cardiac regenerative therapies in the future.
Supporting Information
Figure S1. Luciferase reporter assays and EMSA for Mesp1 on the Nkx2.5 cardiac
enhancer element. S1A. Besides in HEK 293 and H9c2 cells Mesp1 activated the
Nkx2.5 CE element in atrial HL-1 cells but not in endothelial NFPE cells. Asterisks
indicate significance compared to the control (pcDNA3.1); ** 5 p ,0.01. S1B.
Dose reduction of Mesp1-pcDNA3.1-DNA significantly decreased luciferase
activity in 293 cells; * 5 p ,0.05. S1C. Skipping parts of the Nkx2.5 CE according
to Lien and co-workers [7] led to significant reduction of luciferase activation by
Mesp1 in HEK 293 cells. S1D. Locations of confirmed Mesp1 binding sites on the
Nkx2.5 CE [29] (black triangles). S1E. In vitro translated Mesp1 protein from the
flag-Mesp1-pcDNA3.1 confirmed by an anti-flag antibody in western-blotting
(lane 2). As a control whole cell lysate from 293 cells transfected with the flag-
Mesp1-pCDNA3.1 plasmid was used (lane 1). The predicted molecular weight for
Mesp1 is 37 kDa. S1F. In vitro translated Mesp1 (10 ml) bound to an E-Box-motif
(black triangle at position -29 bp in the Nkx2.5 CE) [29] in an electromobility
shift assay (EMSA). The same amount of unprogrammed reticulocyte lysate (RL)
was applied as a control. Competition assays with untagged mutant (mut, 10-fold
excess) and specific (10-fold excess) probes were performed to ensure specificity.
In vitro binding to another E-Box-motif in the Nkx2.5 CE (at position -9138 bp)
[29] could not be confirmed. S1G. Effect of mutating two Mesp1-binding sites at
positions -9138 bp and -29 bp in the Nkx2.5 CE BP on luciferase activity by Mesp1
in HEK 293 cells (** 5 p ,0.01).
doi:10.1371/journal.pone.0113775.s001 (TIF)
Figure S2. Generation and verification of a double-transgenic dox-inducible Mzf1
overexpressing Nkx2.5 CE eGFP ES cell line and characterization of the tetOMzf1-
Nkx2.5 CE eGFP ES cell line compared to the parent Nkx2.5 CE eGFP ES cells.
S2A. Transduction of Nkx2.5 CE eGFP ES cells with Mzf1 and rtTA lentiviruses.
Scale bars: 200 mm. S2B. Dox-inducible expression of Mzf1 could be confirmed in
three expanded clones (cl. 42, 44 and 64). S2C.+D. Confirmation of sensitivity for
dox-inducible Mzf1 expression in clone 64. S2E. The morphology of tetOMzf1-
Nkx2.5 CE eGFP ES cells with and w/o dox was undistinguishable from the parent
Nkx2.5 CE eGFP ES cells. Scale bars: 200 mm for all panels. S2F. Pluripotency of
tetOMzf1-Nkx2.5 CE eGFP ES cells with and w/o dox was evaluated by
immunostaining with an anti-Sox2 antibody. As a control the parent Nkx2.5 CE
eGFP ES cells were also stained. The negative controls were performed with the
secondary antibody only. Scale bars: 200 mm for all panels. S2G. The morphology
of differentiated tetOMzf1-Nkx2.5 CE eGFP ES cells w/o dox was comparable to
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differentiation. Scale bars: 200 mm for all panels. S2H. A negative effect of
permanent or temporary dox-treatment and by this Mzf1 overexpression on
differentiating tetOMzf1-Nkx2.5 CE eGFP ES cells was excluded by comparison of
the amount of dead cells (evaluated by propidiumiodide staining during flow
cytometry) between the different approaches. S2I. Cell proliferation was evaluated
by MTT assays in tetOMzf1-Nkx2.5 CE eGFP ES cells treated with dox for
different time intervals (control was w/o dox); ** 5 p ,0.01.
doi:10.1371/journal.pone.0113775.s002 (TIF)
Figure S3. Mzf1 upregulation in the tetOMzf1-Nkx2.5 CE eGFP ES cell
differentiation assays with different dox-treatment schedules. S3A. Verification of
Mzf1 upregulation on day eight of in vitro differentiation of tetOMzf1-Nkx2.5 CE
eGFP ES cells by qRT-PCR; * 5 p ,0.05; ** 5 p ,0.01. S3B. Co-staining with an
anti-flag and an anti-GFP antibody (AB) to detect exogenous overexpression of
Mzf1 (red fluorescence) in day 7 differentiated tetOMzf1-Nkx2.5 CE eGFP ES cells
and cardiac progenitor cells (green fluorescence). Scale bars: 200 mm for all panels.
doi:10.1371/journal.pone.0113775.s003 (TIF)
Methods S1. Detailed methods section.
doi:10.1371/journal.pone.0113775.s004 (DOCX)
Table S1. Transcription factor candidates from in silico analysis of the Nx2.5 CE
element in alphabetical order. Boldly printed TFs were chosen for further analysis
by luciferase reporter assays.
doi:10.1371/journal.pone.0113775.s005 (DOCX)
Table S2. Sequences of primer-sets for gene expression analysis by qRT-PCR.
doi:10.1371/journal.pone.0113775.s006 (DOCX)
Video S1. In vitro differentiation of the parent Nkx2.5 CE eGFP ES cell line. Time-
lapse imaging of Nkx2.5 CE eGFP EBs on day eight of in vitro differentiation. The
video is not real-time but assembled from single pictures photographed in a time
series. Therefore beating frequency is an artifact of exposure time. The video
displays 50–70 images. Magnification is 1006.
doi:10.1371/journal.pone.0113775.s007 (MPG)
Video S2. In vitro differentiation of tetOMzf1-Nkx2.5 CE eGFP ES cells w/o dox
led to eGFP positive beating areas undistinguishable from the parent Nkx2.5 CE
eGFP ES cell line. Time-lapse imaging of tetOMzf1-Nkx2.5 CE eGFP EBs on day
eight of in vitro differentiation w/o dox. The video is not real-time but assembled
from single pictures photographed in a time series. Therefore beating frequency is
an artifact of exposure time. The video displays 50-70 images. Magnification is
1006.
doi:10.1371/journal.pone.0113775.s008 (MPG)
Video S3. In vitro differentiation of tetOMzf1-Nkx2.5 CE eGFP ES cells with dox
from day 5 led to eGFP positive beating areas undistinguishable from the parent
Nkx2.5 CE eGFP ES cell line. Time-lapse imaging of tetOMzf1-Nkx2.5 CE eGFP
EBs on day eight of in vitro differentiation with dox from day 5. The video is not
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PLOS ONE | DOI:10.1371/journal.pone.0113775 December 1, 2014 21 / 24real-time but assembled from single pictures photographed in a time series.
Therefore beating frequency is an artifact of exposure time. The video displays 50–
70 images. Magnification is 1006.
doi:10.1371/journal.pone.0113775.s009 (MPG)
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